AstraZeneca's Imfinzi combined with chemotherapy in TOPAZ-1 trial showed a 26% risk reduction in death for advanced biliary tract cancer patients.
AstraZeneca's Imfinzi (durvalumab) combined with chemotherapy in the TOPAZ-1 Phase 3 trial showed a 26% risk reduction in death for advanced biliary tract cancer patients, with a median overall survival of 12.9 months for the Imfinzi combo vs. 11.3 months for chemotherapy alone. Twice as many patients were alive at three years in the Imfinzi group.
April 16, 2024
6 Articles